Richard J. Markham

Richard J. Markham has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Acura Pharmaceuticals, Inc, NephroGenex, Inc. and Anacor Pharmaceuticals, Inc. Between 24 March 2009 and 13 February 2018, the trades on record add up to 20 filings.

In open-market terms, that means 1 purchase worth €6.9M on one side and 10 sales worth €563k on the other. Taken together, the purchases exceed the sales by €6.4M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants.

Most recently, on 15 February 2018, the filings show a share grant in Vaxart, Inc. The last insider purchase was made public on 19 February 2014, 4,630 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.